Parkinson's disease is a chronic neurological motor disorder, primarily affecting the dopaminergic cells of the brain, it is the second most common age-related neurodegenerative disorder after Alzheimer’s disease
The Global Parkinson's Disease Treatment Market was valued at $ Bn in 2018 and is forecasted to grow at a strong % CAGR between 2018 and 2026, resulting in 2026 global sales of $ Bn. The market-driven growing ageing population and the rising prevalence of Parkinson’s are some of the components boosting the market. In addition, combination treatments which aids in prolonged action of unremitting dopaminergic stimulation medicines, gene therapy and neural transplantation is expected to drive the industry growth
The Global Parkinson's Disease Treatment Market is segmented on the basis of Drug Class , Route of Administration, and Region.
Based on the Drug Class: Decarboxylase Inhibitor, Dopamine Agonist, Monoamino Oxidase Type B (MOA-B) Inhibitor, Catechol-O-Methyltransferase (COMT) Inhibitors, Others
Based on the Route of Administration: Injectables, Oral, Transdermal
Based on Region: North America, Asia-Pacific, Europe, and LAMEA. Among that Asia pacific is projected to witness high growth during the forecasted period due to developing several headache cases and growing public awareness about the disease. For the most part, India and China are significant market has there is a high existences headache in these countries. Moreover, migraine continues to be an undertreated disease and underdiagnosed in India, resulting from myths and misconceptions surrounding the illness including incorrect diagnosis and triggers in the Indian migraine patients are similar to other populations but for dietary factors
The key players of the Global Parkinson's Disease Treatment Market include Teva Pharmaceutical Industries Ltd, Abbvie Inc, Boehringer Ingelheim Gmbh, Novartis AG, Sanofi S.A, GlaxoSmithKline plc, F. Hoffmann-La Roche AG and more
Report Description: The report covers in-depth analysis of the Global Parkinson's Disease Treatment Market. The report assesses the market products pipeline by Route of Administration (Injectables, Oral, Transdermal) by Drug Class (Decarboxylase Inhibitor, Dopamine Agonist, Monoamino Oxidase Type B (MOA-B) Inhibitor, Catechol-O-Methyltransferase (COMT) Inhibitors, Others), by Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa). In addition, the report includes key insights on other development activities, including (but not limited to) – licensing (In and Out), collaborations, acquisitions, reimbursement, patent, and regulatory designations.
The report includes in-depth company profiles of key players in the Global Parkinson's Disease Treatment Market. The company profile includes key information on the overview, financial highlights, product portfolio, business strategies, and key recent developments.
The report highlights information on emerging companies with potentially disruptive technologies and new market entrants.
Data Collation (Primary & Secondary)
In-house Estimation (Based on proprietary databases and Models)
Market-related information is assembled from both primary and secondary sources.
Primary sources involved participants from all global stakeholders such as experts from several related industries and suppliers that have been interviewed to obtain and verify critical information as well as to assess prospects of the market. The participants included are CXOs, VPs, and managers. Plus, our in-house industry experts having decades of industry experience contribute their consulting and advisory services.
Secondary sources include public sources such as regulatory frameworks, government IT spending, government demographic indicators, industry association statistics, and company publications annual reports press releases along with paid sources such as Factiva, OneSource, Bloomberg among others.
Top-down and bottom-up approaches: The overall market size was used in the top-down approach to estimate the sizes of other individual submarkets (mentioned in the market segmentation by product, type of manufacturing, and disease) through percentage splits from secondary and primary research. The bottom-up approach was also implemented (wherever applicable) for data extracted from secondary research to validate the market segment revenues obtained.